OSE Immunotherapeutics granted Servier an option to license exclusive, worldwide rights to develop and commercialize Effi-7. The humanized mAb targeting IL-7 receptor (CD127) is in preclinical testing to treat ulcerative colitis (UC). OSE will continue development within UC through Phase II testing, after which Servier will lead development. Servier plans to begin preclinical testing in Sjögren’s syndrome.
OSE is eligible to receive up to €272 million ($284.6 million), including €10.3 million ($10.7 million) up front and €30 million ($31.4 million) split as a two-step option exercise fee. OSE said the second payment is planned after Phase II completion. The remainder is linked to clinical, regulatory and sales milestones. OSE is also eligible for double-digit royalties. Servier did not respond to inquiries...
BCIQ Target Profiles